Results 151 to 160 of about 111,213 (213)

Impact of China's national drug price negotiation on pharmaceutical firms' innovation activities. [PDF]

Front Public Health
Xu H, Wang J, Zhou Q.
europepmc   +1 more source

Patients on statins with elevated transaminases: Frequency of follow‐up creatine kinase testing and gastroenterology referral

British Journal of Clinical Pharmacology, EarlyView.
Abstract Purpose To quantify how often creatine kinase (CK) is measured after newly elevated aminotransferases in statin users, and whether absent CK data are associated with gastroenterology (GI) referrals. Methods Retrospective chart review of adult outpatients on statins with a first alanine/aspartate aminotransferase (ALT/AST) elevation during a 5 ...
Faris Shweikeh, Anas Kartoumah, Rajshri Joshi, Anjali Nadihaan, Mohammed Mouchli, Inderprit Singh   +5 more
wiley   +1 more source

The pharmaceutical industry's multifaceted role in neglected tropical disease control: from market failure to global health innovation. [PDF]

Trop Med Health
Sanchez JD.
europepmc   +1 more source

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background A rapid progress in the development of advanced therapy medicinal products (ATMPs) has taken place over the past decades. The ATMPs hold great potential but face challenges in the clinical development and the regulatory process.
Allan Cramer, Freja Karuna Hemmingsen Sørup, Marie Lund, Tonny Studsgaard Petersen, Kristian Karstoft   +4 more
wiley   +1 more source

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study. [PDF]

BMJ Open
Grundy Q, Hart D, Lexchin J, Persaud N, Tadrous M, Gagnon MA.   +5 more
europepmc   +1 more source

British National Formulary Guidance on prescribing in pregnancy: A descriptive cross‐sectional study

British Journal of Clinical Pharmacology, EarlyView.
Aim To assess how well pregnancy‐specific guidance within the British National Formulary supports healthcare professionals to facilitate safe and effective medication use. Methods We performed a manifest content analysis of the text of all pregnancy sections within British National Formulary drug monographs, with inductive and iterative coding.
Hannah Johnson, Cleodie Swire, Lakshiv Dhingra, Toqa El‐Nahhas, Michelle Essiam, Salma Muse, Maria Tonkova, Nazmin Begum, Joan Morris, Emma Baker   +9 more
wiley   +1 more source

Post-market surveillance of albendazole tablet brands in Kenya: Implications for deworming programs and clinical outcomes. [PDF]

PLoS Negl Trop Dis
Yator EK, Njogu PM.
europepmc   +1 more source

Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety-reply. [PDF]

Ther Adv Drug Saf, 2015
Simon K.
europepmc   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink, Rosanne E. Huisman, Jan‐Peter van Wieringen, H. J. M. J. (Ineke) Crijns, Florence P. A. M. van Hunsel, Anneke L. M. Passier, Sander Borgsteede, A. C. G. (Toine) Egberts, Laura M. Yates, Eugène P. van Puijenbroek   +9 more
wiley   +1 more source